Vascular Smooth Muscle Cell Plasticity in Atherosclerosis: From Macrophage-like Transdifferentiation to Therapeutic Targeting
- 1First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
- 2Suzhou Institute for Advanced Research, University of Science and Technology of China, Suzhou 215123, China
Abstract
Atherosclerosis remains the leading cause of cardiovascular mortality worldwide. Vascular smooth muscle cells (VSMCs) were long regarded as passive structural elements of the arterial wall, but they are now recognized as highly plastic cells capable of transdifferentiating into macrophage-like cells (MLCs). This conversion promotes plaque inflammation, matrix degradation, and necrotic core expansion, yet the mechanisms that control it remain poorly defined. This review synthesizes current understanding of the multilayered regulatory networks that govern VSMC-to-MLC transdifferentiation. These networks couple upstream signaling through MAPK, Notch, TGF-β, and PI3K/AKT to master transcription factors such as KLF4, IRF7, and ZEB2. They further extend to epigenetic mechanisms encompassing DNA methylation, histone modifications, non-coding RNAs, and metabolic reprogramming involving cholesterol efflux and lipophagy. We then assess therapeutic strategies that prevent or reverse this conversion, including miRNA replacement, kinase inhibition, LXR activation and autophagy induction. We further highlight unresolved questions on MLC heterogeneity, reversibility, and targeted delivery, outlining priorities for translating these insights into clinical benefit.
Related
- Macrophage functional plasticity in periodontitis: microenvironmental regulation, disease progression, and therapeutic targeting
- TREM2 encodes plaque macrophage plasticity to mediate atherosclerosis regression
- Sexually dimorphic transdifferentiation of endothelial cells in atherosclerosis
- Macrophage plasticity in inflammatory and tumor microenvironments: mechanisms, evidence, and therapeutic opportunities
- Macrophage PIM1 Drives Atherosclerosis by Enhancing Foam Cell Formation Via CD36
BibTeX
@article{zhang2026vascular,
title = {{Vascular Smooth Muscle Cell Plasticity in Atherosclerosis: From Macrophage-like Transdifferentiation to Therapeutic Targeting}},
author = {Muxin Zhang and Zicheng Wang and Mengkai Lu and Jiaqi Hao and Yunlun Li},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27209140},
url = {https://www.mdpi.com/1422-0067/27/20/9140},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Vascular Smooth Muscle Cell Plasticity in Atherosclerosis: From Macrophage-like Transdifferentiation to Therapeutic Targeting
AU - Muxin Zhang
AU - Zicheng Wang
AU - Mengkai Lu
AU - Jiaqi Hao
AU - Yunlun Li
PY - 2026
DA - 2026/10/15
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27209140
UR - https://www.mdpi.com/1422-0067/27/20/9140
AB - Atherosclerosis remains the leading cause of cardiovascular mortality worldwide. Vascular smooth muscle cells (VSMCs) were long regarded as passive structural elements of the arterial wall, but they are now recognized as highly plastic cells capable of transdifferentiating into macrophage-like cells (MLCs). This conversion promotes plaque inflammation, matrix degradation, and necrotic core expansion, yet the mechanisms that control it remain poorly defined. This review synthesizes current understanding of the multilayered regulatory networks that govern VSMC-to-MLC transdifferentiation. These networks couple upstream signaling through MAPK, Notch, TGF-β, and PI3K/AKT to master transcription factors such as KLF4, IRF7, and ZEB2. They further extend to epigenetic mechanisms encompassing DNA methylation, histone modifications, non-coding RNAs, and metabolic reprogramming involving cholesterol efflux and lipophagy. We then assess therapeutic strategies that prevent or reverse this conversion, including miRNA replacement, kinase inhibition, LXR activation and autophagy induction. We further highlight unresolved questions on MLC heterogeneity, reversibility, and targeted delivery, outlining priorities for translating these insights into clinical benefit.
SN - 1422-0067
ER -